ZYNERBA PHARMACEUTICALS, INC. Clinical Trials
Studies registered on ClinicalTrials.gov (U.S. National Library of Medicine) with the company as lead sponsor or collaborator, newest start first. Values are as registered.
- 2020-02-19: Study NCT05149898; Company role Collaborator; Phase Phase 2; Status Completed.
- 2018-11-09: Study NCT03802799; Company role Lead sponsor; Phase Phase 2, Phase 3; Status Active not recruiting.
- 2018-06-12: Study NCT03614663; Company role Lead sponsor; Phase Phase 2, Phase 3; Status Completed.
| Start date | Study | Company role | Phase | Status | Conditions | Enrollment | Completion date |
|---|---|---|---|---|---|---|---|
| 2020-02-19 | NCT05149898 Open-Label Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents With 22q11.2 Deletion Syndrome (INSPIRE) | Collaborator Lead: Harmony Biosciences Management, Inc. | Phase 2 | Completed Results posted | 22Q11.2 Deletion Syndrome | 20 | 2022-11-09 |
| 2018-11-09 | NCT03802799 Open Label Extension to Assess the Long-Term Safety and Tolerability of ZYN002 in Children and Adolescents With FXS | Lead sponsor | Phase 2, Phase 3 | Active not recruiting | Fragile X Syndrome | 476 | 2026-06-30 |
| 2018-06-12 | NCT03614663 Clinical Study Of caNNabidiol in childrEn and adolesCenTs With Fragile X (CONNECT-FX) | Lead sponsor | Phase 2, Phase 3 | Completed Results posted | Fragile X Syndrome | 212 | 2020-06-14 |